Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC

Phase 3

Active, not recruiting

• Conditions: Triple Negative Breast Cancer
• Interventions: Biological: adagloxad simolenin combined with OBI-821; Device: Globo H IHC Assay; Other: Standard of care treatment

• Registration Number: NCT03562637
• Lead Sponsor: OBI Pharma, Inc

Brief Summary

The GLORIA study is a Phase III, randomized, open-label study to prospectively evaluate the efficacy and safety of adagloxad simolenin (OBI 822)/OBI-821 in the adjuvant treatment of patients with high risk, early stage Globo-H Positive TNBC.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2018-06-06
• Study First Submitted QC: 2018-06-08
• Study First Posted: 2018-06-19
• Study Start: 2018-12-05
• Status Verified: 2025-05
• Last Update Submitted: 2025-05-06
• Last Update Posted: 2025-05-09
• Primary Completion: 2025-12-30
• Study Completion: 2027-12-30

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 575

Inclusion Criteria

• Documented radiographic and histopathologic confirmed primary localized invasive breast cancer.

• Histologically documented TNBC (estrogen receptor negative [ER-]/progesterone receptor negative [PR-]/human epidermal growth factor 2 negative [HER2-]) defined as ER-negative and PR-negative (≤5% positive cells stain by IHC for both ER and PR), and negative HER2/neu- status, confirmed on tumor sample.

• HER2/neu negative will be defined as one of the following criteria:

  • IHC 0 or 1+
  • Single-probe average HER2 gene copy number of <6 signals/nucleus
  • Dual-probe fluorescent in-situ hybridization (FISH) HER2/neu chromosome 17 (CEP17) non-amplified ratio of <2

• Globo H IHC H-score ≥15 from the residual primary site/or lymph node (if primary site is not available) tumor obtained at time of definitive surgery or initial diagnosis (only if surgical tumor sample is not available). Globo H expression will be determined during pre-screening by Central lab. Instructions for submission of slides/tumor tissue blocks are provided in the protocol and study Lab Manual.

• No evidence of metastatic disease in chest, abdomen and pelvis by CT or other adequate imagining during the Screening Phase. Imaging within 3 months prior to randomization is acceptable as baseline scan. Bone scans and imaging of the brain at screening is optional, and should be symptom directed.

• High risk patients with no evidence of disease after completing standard treatment and meeting ONE of the following criteria:

  • Neoadjuvant chemotherapy followed by definitive surgery: Residual invasive disease following neoadjuvant chemotherapy defined as: A contiguous focus of residual invasive cancer in the surgical breast specimen measuring ≥1 cm in diameter and/or with residual invasive cancer in at least one axillary node (micrometastases or macrometastases), as determined by local pathology review.
  • Definitive surgery followed by adjuvant chemotherapy: Pathological Prognostic Stage IIB, Stage IIIA , Stage IIIB, or Stage IIIC disease according to the 8th edition of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual.

• Must have completed at least 4 cycles of a standard taxane and anthracycline-based multi-agent chemotherapy regimen (or a taxane-only regimen if the patient is ineligible for anthracycline treatment) either in the neoadjuvant or adjuvant setting (e.g., National Comprehensive Cancer Network recommended regimens):.

  • Randomization must occur (a) within 16 weeks after definitive surgery and radiation therapy (if radiation therapy administered) in patients who received neoadjuvant multiagent chemotherapy or, (b) for patients receiving adjuvant multiagent chemotherapy (not including capecitabine, immune checkpoint inhibitor), within 16 weeks after the completion of the adjuvant multiagent chemotherapy and radiation therapy (if radiation therapy administered). Note: patients may be randomized and initiate study treatment concurrent with adjuvant SOC therapy (observation, capecitabine, immune checkpoint inhibitor ± capecitabine).

• Randomization must occur (a) within 16 weeks after definitive surgery and radiation therapy (if radiation therapy administered) in patients who received neoadjuvant multiagent chemotherapy or, (b) for patients receiving adjuvant multiagent chemotherapy (not including capecitabine, immune checkpoint inhibitor), within 16 weeks after the completion of the adjuvant multiagent chemotherapy and radiation therapy (if radiation therapy administered). Note: patients may be randomized and initiate study treatment concurrent with adjuvant SOC therapy (observation, capecitabine, immune checkpoint inhibitor ± capecitabine).

• All treatment-related toxicities resolved to Grade <1 on National cancer institute Common Terminology Criteria for Adverse Events (NCI-CTCAE version 5.0) criteria (except hair loss and ≤Grade 2 neuropathy, which are acceptable).

• Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1.

• Females must be either of non-childbearing potential, i.e., surgically sterilized (have documented sterilization, bilateral oophorectomy/salpingectomy at least 3 months before the start of the trial and/or hysterectomy), or one year postmenopausal; or if of childbearing potential must have a negative pregnancy test (urine or serum) at screening.

• Males and females of childbearing potential and their partners must be willing to use effective contraception during the entire Treatment Phase and for at least 4 weeks (28 days) after the last dose of study treatment.

• Adequate hematological, hepatic and renal function as defined below:

  • Absolute neutrophil count (ANC) ≥1,500/µL
  • Platelets ≥75,000/µL
  • Hemoglobin ≥8.5g/dL
  • Serum creatinine ≤1.5 × upper limit of normal (ULN) or calculated creatinine clearance ≥55 mL/min for subjects with creatinine levels >1.5 × institutional ULN (glomerular filtration rate can also be used in place of creatinine or creatinine clearance may be calculated per institutional standard)
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3 × ULN
  • Alkaline Phosphatase (ALP) ≤2.5 × ULN
  • Serum total bilirubin ≤1.5 × ULN (unless Gilbert's disease is documented)

• Consent to participate with a signed and dated Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved patient informed consent for the study prior to beginning any specific study procedures.

• Ability to understand and willingness to complete all protocol required procedures.

Exclusion Criteria

• Local recurrence of or previous history of ipsilateral or contralateral invasive breast cancer within 10 years prior to randomization [for synchronous tumors see Exclusion criteria #3]
• Definitive clinical or radiologic evidence of metastatic disease
• Synchronous bilateral breast cancer, unless both tumors are confirmed as TNBC.
• Have received any anti-cancer vaccines
• Concomitant treatment with anticancer therapy other than adjuvant SOC therapy (capecitabine; immune checkpoint inhibitor), or other investigational therapy, if expected during the study
• A history of other malignancies (except appropriately treated melanoma in situ, non melanoma skin carcinoma, carcinoma in situ of the uterine cervix, follicular or papillary thyroid cancer or other non-breast malignancies with a similar outcome to those mentioned above) within 5 years prior to randomization.
• Have any active autoimmune disease or disorder that requires systemic immunosuppressive/immunomodulatory therapy. NOTE: Autoimmune diseases that are confined to the skin (e.g., psoriasis) that can be treated with topical steroids alone are allowed during the study.
• Oral/parenteral corticosteroid treatment (>5 mg/day of prednisone/equivalent), within 2 weeks prior to randomization or anytime during the study. NOTE: inhaled steroids for treatment of asthma; and topical steroids are allowed during the study.
• Any known uncontrolled concurrent illness that would limit compliance with study requirements, including but not limited to ongoing or active infections, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, psychiatric disorders, or substance abuse.
• Any known hypersensitivity to active/inactive ingredients in the study drug formulation or known severe allergy or anaphylaxis to fusion proteins.
• Prior receipt of a glycoconjugate vaccine for cancer immunotherapy.
• Known history or positive for human immunodeficiency virus (HIV positive), unless on effective anti-retroviral therapy with undetectable viral load within 6 months of therapy (note: HIV testing not required for study entry).
• Known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection prior to randomization. Patients who have completed curative therapy and have undetectable viral load for HCV are eligible. For patients with evidence of chronic HBV infection, the HBV viral load must be undetectable on suppressive therapy. (note: HBV/HCV testing is not required for study entry).
• Any condition, including significant diseases and/or laboratory abnormalities that would place the patient at unacceptable risk for study participation.
• Currently pregnant or breastfeeding women.
• Currently participating in or has participated in a breast cancer therapeutic clinical trial within 4 weeks (28 days) prior to randomization.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Adagloxad simolenin + OBI-821 in conjunction with SOC	adagloxad simolenin combined with OBI-821	Participants will be administered adagloxad simolenin combined with OBI-821 for up to a total of 21 subcutaneous injections over a period of 100 weeks. Patient will also receive standard of care (SOC) treatment.
Adagloxad simolenin + OBI-821 in conjunction with SOC	Standard of care treatment	Participants will be administered adagloxad simolenin combined with OBI-821 for up to a total of 21 subcutaneous injections over a period of 100 weeks. Patient will also receive standard of care (SOC) treatment.
Adagloxad simolenin + OBI-821 in conjunction with SOC	Globo H IHC Assay	Participants will be administered adagloxad simolenin combined with OBI-821 for up to a total of 21 subcutaneous injections over a period of 100 weeks. Patient will also receive standard of care (SOC) treatment.
Standard of Care treatment	Globo H IHC Assay	Study visit intervals will be identical to those in Arm 1. Patient will receive standard of care (SOC) treatment.
Standard of Care treatment	Standard of care treatment	Study visit intervals will be identical to those in Arm 1. Patient will receive standard of care (SOC) treatment.

Primary Outcome Measures

Name	Time	Method
Measuring the effect of adagloxad simolenin (OBI-822)/OBI-821 treatment on improving invasive disease free survival (IDFS) in the study population.	5 years	The outcome measure of the study is IDFS, defined by the STEEP system as the first occurrence of the time from the date of randomization to the date of first invasive disease recurrence (local, regional or distant), the date of secondary primary invasive cancer (breast or not), or the date of death from any cause.

Secondary Outcome Measures

Name	Time	Method
Measuring the impact of adagloxad simolenin (OBI-822)/OBI-821 treatment in the study population on Overall Survival (OS).	7 years	OS is defined as the time from randomization to date of death from any cause
Measuring the impact of adagloxad simolenin (OBI-822)/OBI-821 treatment in the study population on Breast cancer-free interval (BCFI).	7 years	BCFI is defined by the STEEP system as the first occurrence of the time from the date of randomization to the date of the first invasive disease recurrence (local, regional or distant), the date of ductal carcinoma in situ (ipsilateral or contralateral), or the date of death from breast cancer
Measuring the impact of adagloxad simolenin (OBI-822)/OBI-821 treatment in the study population on Distant disease-free survival (DDFS).	7 years	DDFS is defined by the STEEP system as the first occurrence of the time from the date of randomization to the date of the first distant disease recurrence, the date of the second primary invasive cancer (non-breast), or the date of death from any cause
Incidence and severity of adverse events (AEs) [Time Frame: AEs will be noted as it occurs, with a timeframe from beginning of randomization to 4 weeks after last dose of study treatment.]	2 years	Adverse Events will be graded and recorded by investigators per National Cancer Institute-Common Terminology Criteria for Adverse Events version 5.0 (NCI-CTCAE v5.0).
Measuring the impact of adagloxad simolenin (OBI-822)/OBI-821 treatment in the study population on Quality of Life (QoL).	7 years	QoL defined as time to definitive deterioration in Health-related Quality of Life (HRQOL) using the global health status/QoL scale from European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30) and the European Quality of Life 5 Dimensions 5 Levels (EQ-5D-5L). QoL baseline established at randomization.; Definitive deterioration defined as a 5% worsening relative to baseline in the HRQOL scale score from EORTC QLQ-C30 questionnaires with no subsequent improvement above threshold, scored with the EORTC QLQ-C30 v3.0 Scoring Manual. The EQ-5D-5L questionnaire assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, rated by the patient. It is a standardized measure of health status to provide a simple, generic measure of health for clinical and economic appraisal. 28 questions have a 4 point scale: not at all(1) to very much(4). 2 questions have a 7-point scale: very poor (1) to excellent(7).

Trial Locations

Locations (128)

CI Reg. Oncol. Dispanser; 🇺🇦 Zhytomyr, Ukraine

Moores UCSD Cancer Center; 🇺🇸 La Jolla, California, United States

Kaiser Permanente Medical Center; 🇺🇸 San Diego, California, United States

UCSF Helen Diller Family Comprehensive Cancer Centre; 🇺🇸 San Francisco, California, United States

Miami Cancer Institute; 🇺🇸 Miami, Florida, United States

University of Chicago Medical; 🇺🇸 Chicago, Illinois, United States

University of Maryland Greenbaum Comprehensive Cancer Center; 🇺🇸 Baltimore, Maryland, United States

Henry Ford Medical Center; 🇺🇸 Detroit, Michigan, United States

Rutgers Cancer Institute of New Jersey; 🇺🇸 New Brunswick, New Jersey, United States

Magee-Womens Hospital of UPMC; 🇺🇸 Pittsburgh, Pennsylvania, United States

University of Texas Health Science Center at San Antonio; 🇺🇸 San Antonio, Texas, United States

Bons Secours St. Francis Medical Oncology Center; 🇺🇸 Midlothian, Virginia, United States

Northwest Medical Specialties, PLLC; 🇺🇸 Tacoma, Washington, United States

Westmead Hospital; 🇦🇺 Westmead, New South Wales, Australia

Cancer Care Service, Hervey Bay Hospital; 🇦🇺 Urraween, Queensland, Australia

Victoria Breast & Oncology Care; 🇦🇺 East Melbourne, Victoria, Australia

Cabrini Malvern; 🇦🇺 Malvern, Victoria, Australia

Breast Cancer Research Centre; 🇦🇺 Nedlands, Western Australia, Australia

St Vincent's Hospital Sydney; 🇦🇺 Darlinghurst, Australia

Gosford Hospital; 🇦🇺 Gosford, Australia

St John of God Murdoch Hospital; 🇦🇺 Murdoch, Australia

Eastern Health - Maroondah Hospital; 🇦🇺 Ringwood East, Australia

Hospital Sao Rafael; 🇧🇷 Salvador, Bahia, Brazil

Suporte Nutricional e Quimioterapia; 🇧🇷 Fortaleza, Ceara, Brazil

Centro de Avaliacao de Medicamentos e Especialidades de Pesquisa; 🇧🇷 Serra, Espirito Santo, Brazil

Instituto Mario Penna; 🇧🇷 Belo Horizonte, Minas Gerais, Brazil

Maternidade e Cirurgia Nossa Senhora do Rocio; 🇧🇷 Campo Largo, Parana, Brazil

Hospital das Clinicas - Universidade Federal do Parana; 🇧🇷 Curitiba, Parana, Brazil

Centro de Tratamento Oncologico LTDA - CTO; 🇧🇷 Belém, Para, Brazil

Hospital do Capibaribe; 🇧🇷 Recife, Pernambuco, Brazil

Real Hospital Portugues de Beneficencia de Pernambuco; 🇧🇷 Recife, Pernambuco, Brazil

BHI of Omsk region "Clinical Oncology Dispensary"; 🇷🇺 Omsk, Russian Federation

Centro de Pesquisa Vencer & Oncolinca; 🇧🇷 Teresina, Piaui, Brazil

Hospital de Clinicas de Porto Alegre; 🇧🇷 Barretos, Rio Grande Do Sul, Brazil

Oncosite-Centro de Pesquisa Clinica em Oncologia; 🇧🇷 Ijuí, Rio Grande Do Sul, Brazil

Hospital Escola da Universidade Federal de Pelotas; 🇧🇷 Pelotas, Rio Grande Do Sul, Brazil

Irmandade da Santa Casa de Misericordia de Porto Alegre; 🇧🇷 Porto Alegre, Rio Grande Do Sul, Brazil

Pontificia Universidade Catolica do Rio Grande do Sul (PUCRS) - Hospital Sao Lucas; 🇧🇷 Porto Alegre, Rio Grande Do Sul, Brazil

Hospital de Amor Amazonia; 🇧🇷 Porto Velho, Rondona, Brazil

Centro Oncologico de Roraima; 🇧🇷 Boa Vista, Roraima, Brazil

Clinica Supera; 🇧🇷 Chapeco, Santa Catarina, Brazil

Clinica de Neoplasias Litoral - Itajai; 🇧🇷 Itajaí, Santa Catarina, Brazil

Hospital de Cancer de Barretos; 🇧🇷 Barretos, Sao Paulo, Brazil

Hospital Amaral Carvalho de Jau; 🇧🇷 Jaú, Sao Paulo, Brazil

Centro de Pesquisa Clinica em Hematologia e Oncologia; 🇧🇷 Santo André, Sao Paulo, Brazil

Clinicia de Pesquisa e Centro de Estudos em Oncologia Ginecologica e Mamaria; 🇧🇷 São Paulo, Sao Paulo, Brazil

Instituto Brasileiro de Controle do Cancer; 🇧🇷 São Paulo, Sao Paulo, Brazil

Instituto do Cancer do Estado de San Paulo; 🇧🇷 São Paulo, Sao Paulo, Brazil

Cancer Hospital Chinese Academy of Medical Sciences; 🇨🇳 Beijing, Beijing, China

Beijing Cancer Hospital; 🇨🇳 Beijing, Beijing, China

Sun Yat-Sen University Cancer Center; 🇨🇳 Guangzhou, Guangdong, China

The First Affiliated Hospital of Guangxi Medical University; 🇨🇳 Nanning, Guangxi, China

Harbin Medical University Cancer Hospital; 🇨🇳 Harbin, Heilongjiang, China

Hubei Cancer Hospital; 🇨🇳 Wuhan, Hubei, China

Xiangya Hospital Central South University; 🇨🇳 Changsha, Hunan, China

Hunan Cancer Hospital; 🇨🇳 Changsha, Hunan, China

Jiangsu Province Hospital; 🇨🇳 Nanjing, Jiangsu, China

The First Hospital of Jilin University; 🇨🇳 Changchun, Jilin, China

Liaoning Cancer Hospital and Institute; 🇨🇳 Shenyang, Liaoning, China

Netcare Milpark Hospital; 🇿🇦 Johannesburg, Gauteng, South Africa

The First Hospital of China Medical University; 🇨🇳 Shenyang, Liaoning, China

Sichuan Provincial People's Hospital; 🇨🇳 Chengdu, Sichuan, China

Tianjin Cancer Hospital; 🇨🇳 Tianjin, Tianjin, China

Sir Run Run Shaw Hospital; 🇨🇳 Hangzhou, Zhejiang, China

Zhejiang Cancer Hospital; 🇨🇳 Hangzhou, Zhejiang, China

Cancer Institute and Hospital; 🇨🇳 Beijing, China

Queen Mary Hospital; 🇭🇰 Hong Kong, Hong Kong

Dong-A University Hospital; 🇰🇷 Busan, Korea, Republic of

National Cancer Center; 🇰🇷 Goyang-si, Korea, Republic of

Inha University Hospital; 🇰🇷 Incheon, Korea, Republic of

Seoul National University Bundang Hospital; 🇰🇷 Seongnam-si, Korea, Republic of

Seoul National University Hospital; 🇰🇷 Seoul, Korea, Republic of

Asan Medical Center; 🇰🇷 Seoul, Korea, Republic of

The Catholic University of Korea, Seoul St. Mary's Hospital; 🇰🇷 Seoul, Korea, Republic of

Severance Hospital, Yonsei University Health System; 🇰🇷 Seoul, Korea, Republic of

The Catholic University of Korea, St. Vincent's Hospital; 🇰🇷 Suwon-si, Korea, Republic of

Clinica Oncor - Centro de Infusion e Investigacion Oncologia de Satillo; 🇲🇽 Saltillo, Coahuila, Mexico

Instituto Nacional de Cancerologia; 🇲🇽 Ciudad de mexico, Del Tialpan, Mexico

Centro Oncologico Estatal Instituto de Seguridad Social del Estado de Mexico y Municipios; 🇲🇽 Toluca, Estado De Mexico, Mexico

Investigacion Biomedica para el Desarrollo de Farmacos; 🇲🇽 Zapopan, Jalisco, Mexico

Sociedad Administradora de Servicios de Salud S.C.; 🇲🇽 Morelia, Michoacan, Mexico

Centro Medico Zambrano Hellion; 🇲🇽 San Pedro Garza Garcia, Nuevo Leon, Mexico

Investigacion Biomedica para el Desarrollo de Farmacos, S.A. de. C.V; 🇲🇽 Aguascalientes, Mexico

Centro Estatal de Cancerologia; 🇲🇽 Chihuahua, Mexico

Icaro Investigaciones en Medicina S.A. de C.V.; 🇲🇽 Chihuahua, Mexico

Scientia Investigacion Clinica S.C.; 🇲🇽 Chihuahua, Mexico

Instituto Nacional de Enfermedades Neoplasicas; 🇵🇪 Lima, Surquillo, Peru

Instituto Regional de Enfermedades Neoplasicas del Sur; 🇵🇪 Arequipa, Peru

Hospital Nacional Edgardo Rebagliati Martins, Unidad de Investigacion de Oncologia Medica; 🇵🇪 Lima, Peru

Unidad de Investigacion - Oncologia Medica Clinica San Felipe; 🇵🇪 Lima, Peru

Hospital Maria Auxiliadora; 🇵🇪 Lima, Peru

University Clinical Centre - Hospital, Teaching Dept of Oncology and Radiotherapy; 🇵🇱 Gdańsk, Poland

Independent Public Healthcare Facility University Hospital in Cracow; 🇵🇱 Kraków, Poland

Central Teaching Hospital of the MOI in Warsaw; 🇵🇱 Warsaw, Poland

Maria Sklodowska-Curie National Institute of Oncology; 🇵🇱 Warsaw, Poland

Contemporary Therapy Centre; 🇵🇱 Łódź, Poland

Polish Mother's Memorial Hospital Research Instistute; 🇵🇱 Łódź, Poland

Nat. Research Mordovia State University; 🇷🇺 Saransk, Republic Of Mordovia, Russian Federation

SBIH of Arkhangelsk region "Arkhangelsk Clinical Oncological Dispensary"; 🇷🇺 Arkhangelsk, Russian Federation

Krasnoyarsk Territorial Clinical Oncology Center named after A.I. Kryzhanovsky; 🇷🇺 Krasnoyarsk, Russian Federation

FSBSI "Russian Oncological Scientific Center n.a. N.N. Blokhin"; 🇷🇺 Moscow, Russian Federation

SBIH of Moscow city "Moscow city oncology hospital №62" of Moscow Healthcare department; 🇷🇺 Moscow, Russian Federation

Orenburg Regional Clinical Oncological Center; 🇷🇺 Orenburg, Russian Federation

N.N. Petrov National Medical Research Center of Oncology; 🇷🇺 Pesochnyy, Russian Federation

LLC Medaid; 🇷🇺 Saint Petersburg, Russian Federation

SPb SBIH "City Clinical Oncological Dispensary"; 🇷🇺 Saint-Petersburg, Russian Federation

Klinika Luch, Ltd.; 🇷🇺 St. Petersburg, Russian Federation

SBHI "Volgograd Regional Oncology Dispensary #3"; 🇷🇺 Volzhskiy, Russian Federation

SBIH of Yaroslavl region "Regional Clinical Oncological Hospital"; 🇷🇺 Yaroslavl, Russian Federation

Wits Clinical Research, a division of Wits Health Consortium (Pty) Ltd; 🇿🇦 Johannesburg, Gauteng, South Africa

Medical Oncology Centre of Rosebank; 🇿🇦 Johannesburg, Gauteng, South Africa

Changhua Christian Hospital; 🇨🇳 Changhua, Taiwan

Kaohsiung Medical University Chung-Ho Memorial Hospital; 🇨🇳 Kaohsiung, Taiwan

Chung Shan Medical University Hospital; 🇨🇳 Taichung, Taiwan

National Cheng Kung University Hospital; 🇨🇳 Tainan, Taiwan

National Taiwan University Hospital; 🇨🇳 Taipei, Taiwan

Chang Gung Medical Foundation Linkou; 🇨🇳 Taipei, Taiwan

Taipei Veterans General Hospital; 🇨🇳 Taipei, Taiwan

Koo Foundation Sun Yat-Sen Cancer Center; 🇨🇳 Taipei, Taiwan

Tri-Service General Hospital; 🇨🇳 Taipei, Taiwan

Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine; 🇺🇦 Dnipro, Ukraine

City Clinical Hospital #4; 🇺🇦 Dnipro, Ukraine

CI Transcarpathian Cl Onc Center Dep of Surgery#1 SHEI Ivano-Frankivsk NMU; 🇺🇦 Ivano-Frankivsk, Ukraine

CI of Healthcare Regional Clinical Specialized Dispensary of the Radiation Protection; 🇺🇦 Kharkiv, Ukraine

CI of Kherson Reg Council Kherson Regional Oncologic Dispensary; 🇺🇦 Kherson, Ukraine

Medical Center of Vision Partner; 🇺🇦 Kyiv, Ukraine

Medical Center Verum; 🇺🇦 Kyiv, Ukraine

Kyiv Сity Clinical Oncological Center; 🇺🇦 Kyiv, Ukraine